Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.
about
Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protectionInducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingR5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes.Update on animal models for HIV research.Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesAIDS and optic neuritis in a rhesus monkey infected with the R5 clade C SHIV-1157ipd3N4Placental Hofbauer cells assemble and sequester HIV-1 in tetraspanin-positive compartments that are accessible to broadly neutralizing antibodies.Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cellsGeneration and evaluation of clade C simian-human immunodeficiency virus challenge stocksMultimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.No acquisition: a new ambition for HIV vaccine development?Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection.SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction.Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaquesPathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virusPassive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.Coreceptor use in nonhuman primate models of HIV infection.Development of SHIVs with circulating, transmitted HIV-1 variants.High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses.
P2860
Q27332360-9C94ECE2-C3B3-4B11-96B4-1A56627D9945Q33392865-DBF4B49C-B3F1-44C8-A072-5FFEAE4E4BFBQ33640144-96985362-BE41-4E51-A209-FBBE7F46DC36Q33729355-51BA9315-3829-4786-AD30-A589347BDE6DQ33835488-96C26D2D-C05E-442E-AAA7-9006B8CF2B2AQ34412302-62157C49-3A88-4D8B-8205-F5DD0B9D9FF1Q34575993-C74C5438-2B86-4021-81BF-6896AC8FB1D3Q34625185-56E73785-F916-414C-BF84-7D1F929906D8Q34791232-ABC16CA8-3907-4D08-ABF4-CC17583E921BQ34983220-B76BC8C2-BE06-4328-9E14-1CE6219281E7Q35020445-4D15A091-6E6E-4978-9E72-F70A496632C3Q35076897-47C18AEC-6CA5-43EC-99E4-2582C2B58B8EQ35115599-703D96FC-E7ED-4BB0-88AB-8A13014B4FC5Q35129224-DBF14DC9-5A13-469C-B2BE-7422A4D9D066Q35160124-FA45B898-87B7-4799-825E-F0F46C40FFDBQ35534563-A0914FDC-D3BA-46E5-9098-E3ABA91468DEQ35774679-58916FF9-1484-4903-A93F-27C59CE88B4DQ36397434-1EB6DDA7-ECA6-4920-A837-DA6FEF6312D8Q36745235-95E4B830-9E63-4E69-AD6C-8EF720601C5CQ36827168-A65DC726-4260-49EC-B774-CD709AF27471Q36964284-F05A6BDE-F2C5-4593-A661-79EE7D23E6DBQ37021717-66F32A4F-B642-438F-9E01-7D0E1FA658F5Q37287933-F9DA1CAB-DDA1-45A1-9672-9E8461304809Q37528015-DB1321E1-EEFF-4528-8EC3-674E3C4F6BBFQ37834099-3A236574-ACDC-442E-BFB6-88E367E0215AQ41144765-FFDB176E-735A-4097-A178-86F655F8CEEAQ53682331-59AD119C-F533-4342-8BBC-EA02B85794AA
P2860
Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@ast
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@en
type
label
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@ast
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@en
prefLabel
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@ast
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@en
P2093
P2860
P50
P356
P1433
P1476
Neutralization-sensitive R5-tr ...... recent HIV clade C infection.
@en
P2093
Agnès-Laurence Chenine
Charles Wood
Chipeppo Kankasa
Francis J Novembre
Helena Ong
Hong Zhang
James G Else
Rama Rao Amara
Ricky D Grisson
Robert A Rasmussen
P2860
P304
P356
10.1128/JVI.02066-08
P577
2008-11-19T00:00:00Z